David Wyles, MD

Professor, Medicine-Infectious Disease

FacultyPhoto

Download CV

Medical School
  • MD, Northwestern University The Feinberg School of Medicine (1998)
Undergraduate School
  • BS, Northwestern University (IL) (1993)
Internship
  • University of Colorado (1999)
Residency
  • University of Colorado, Internal Medicine (2001)
Fellowships
  • University of Colorado, Infectious Disease (2004)
Department
Medicine-Infectious Disease

Publications

  • Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun;5(6):ofy103. PubMed PMID: 29977962
  • Luetkemeyer AF, Wyles DL. CROI 2018: Highlights of Viral Hepatitis. Top Antivir Med. 2018 May;26(1):30-38. PubMed PMID: 29727295
  • Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print] PubMed PMID: 29566246
  • Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis. 2018 Feb;5(2):ofy001. PubMed PMID: 29450210
  • Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017 Dec;14(6):229-237. PubMed PMID: 29116550
  • Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis. 2017 Summer;4(3):ofx154. PubMed PMID: 28948180
  • Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2017 Sep 19. [Epub ahead of print] PubMed PMID: 28926120
  • Wyles DL, Luetkemeyer AF. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Top Antivir Med. 2017 Jul Aug;25(3):103-109. PubMed PMID: 28820725
  • Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 Dec;66(6):1794-1804. PubMed PMID: 28688129
  • Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229-238. PubMed PMID: 28650844
  • Luetkemeyer AF, Wyles DL. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2017 May Jun;25(2):84-92. PubMed PMID: 28598793
  • Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017 Dec;37(12):1796-1804. PubMed PMID: 28470938
  • Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Aug;67(2):263-271. PubMed PMID: 28412293
  • Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 1;65(1):6-12. PubMed PMID: 28369210
  • Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. J Infect Dis. 2017 Feb 15;215(4):599-605. PubMed PMID: 28329334
  • Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. J Viral Hepat. 2017 Apr;24(4):280-286. PubMed PMID: 27935166
  • Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Gane EJ. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017 Apr;66(4):703-710. PubMed PMID: 27923693
  • Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA. Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019 Dec 9. [Epub ahead of print] PubMed PMID: 31816111
  • Canfield GS, Henao-Martínez AF, Franco-Paredes C, Zhelnin K, Wilson ML, Shihadeh KC, Wyles D, Gardner EM. Corticosteroids for Posttransplant Immune Reconstitution Syndrome in Cryptococcus gattii Meningoencephalitis: Case Report and Literature Review. Open Forum Infect Dis. 2019 Nov;6(11):ofz460. PubMed PMID: 31737740
  • Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol. 2019 Oct 27. [Epub ahead of print] PubMed PMID: 31656054
  • Wyles DL. Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease. Clin Liver Dis. 2019 Aug;23(3):473-486. PubMed PMID: 31266621
  • Luetkemeyer AF, Wyles DL. CROI 2019: highlights of viral hepatitis. Top Antivir Med. 2019 Apr;27(1):41-49. PubMed PMID: 31137002
  • Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr;6(4):ofz160. PubMed PMID: 31041355
  • Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019 Aug;54(8):752-761. PubMed PMID: 30868245
  • Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 May;70(5):1019-1023. PubMed PMID: 30857780
  • Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. J Viral Hepat. 2019 Mar;26(3):337-349. PubMed PMID: 30421537
  • Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis. 2021 Jan;8(1):ofaa564. PubMed PMID: 33447634
  • Naggie S, Wyles D. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. J Infect Dis. 2020 Nov 27;222(Supplement_9):S741-S744. PubMed PMID: 33245351
  • Sulkowski M, Wyles D. Déjà vu all over again: retreatment of HCV DAA failures- same satisfactory results, same unanswered questions. Clin Infect Dis. 2020 Sep 5. [Epub ahead of print] PubMed PMID: 32887999
  • Vazquez Deida AA, Shihadeh KC, Preslaski CR, Young HL, Wyles DL, Jenkins TC. Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy. Open Forum Infect Dis. 2020 Aug;7(8):ofaa293. PubMed PMID: 32793767
  • Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 Nov 1;75(11):3303-3310. PubMed PMID: 32766700
  • Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis. 2020 Sep 14;222(8):1334-1344. PubMed PMID: 32406487
  • Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther. 2020 Jun;51(12):1384-1396. PubMed PMID: 32352586
  • Fierer DS, Wyles DL. Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy. Open Forum Infect Dis. 2020 Apr;7(4):ofaa095. PubMed PMID: 32296728
  • Balagopal A, Smeaton LM, Quinn J, Venuto CS, Morse GD, Vu V, Alston-Smith B, Cohen DE, Santana-Bagur JL, Anthony DD, Sulkowski MS, Wyles DL, Talal AH. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis. 2020 Jul 23;222(4):601-610. PubMed PMID: 32201883
  • Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol. 2020 Jan;86(1):132-142. PubMed PMID: 31656054
  • Brooks KM, Castillo-Mancilla JR, Morrow M, Mawhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah L, Tehrani A, Jimmerson LC, Roon L, Bushman LR, Anderson PL, Kiser JJ. Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use. J Antimicrob Chemother. 2022 Feb 23. [Epub ahead of print] PubMed PMID: 35194648
  • Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, Prendergast SJ, Rowan SE. Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City. Open Forum Infect Dis. 2022 Feb;9(2):ofab636. PubMed PMID: 35111867
  • Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317. PubMed PMID: 35026142
  • Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2021 Dec;8(12):ofab511. PubMed PMID: 34926713
  • Aronsohn AI, Bhattacharya D, Morgan TR, Wyles DL, Chung RT, McQuillen DP. Reply. Hepatology. 2022 Apr;75(4):1055-1056. PubMed PMID: 34859470
  • Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, Wolfe CR, Ruiz-Palacios GM, Kline S, Regalado Pineda J, Luetkemeyer AF, Harkins MS, Jackson PEH, Iovine NM, Tapson VF, Oh MD, Whitaker JA, Mularski RA, Paules CI, Ince D, Takasaki J, Sweeney DA, Sandkovsky U, Wyles DL, Hohmann E, Grimes KA, Grossberg R, Laguio-Vila M, Lambert AA, Lopez de Castilla D, Kim E, Larson L, Wan CR, Traenkner JJ, Ponce PO, Patterson JE, Goepfert PA, Sofarelli TA, Mocherla S, Ko ER, Ponce de Leon A, Doernberg SB, Atmar RL, Maves RC, Dangond F, Ferreira J, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd L, Tomashek KM, Beigel JH. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1365-1376. PubMed PMID: 34672949
  • Luetkemeyer AF, Wyles DL. CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV. Top Antivir Med. 2021 Jun-Jul;29(3):379-385. PubMed PMID: 34370419
  • Bhatraju PK, Morrell ED, Stanaway IB, Sathe NA, Srivastava A, Postelnicu R, Green R, Andrews A, Gonzalez M, Kratochvil CJ, Kumar VK, Hsiang TY, Gale M Jr, Anesi GL, Wyles D, Broadhurst MJ, Brett-Major D, Mukherjee V, Sevransky JE, Landsittel D, Hung C, Altemeier WA, Gharib SA, Uyeki TM, Cobb JP, Liebler JM, Crosslin DR, Jarvik GP, Segal LN, Evans L, Mikacenic C, Wurfel MM. Angiopoietin-Like4 Is a Novel Marker of COVID-19 Severity. Crit Care Explor. 2023 Jan;5(1):e0827. PubMed PMID: 36600780
  • Postelnicu R, Srivastava A, Bhatraju PK, Wurfelc MM, Anesi GL, Gonzalez M, Andrews A, Lutrick K, Kumar VK, Uyeki TM, Cobb PJ, Segal LN, Brett-Major D, Liebler JM, Kratochvil CJ, Mukherjee V, Broadhurst MJ, Lee R, Wyles D, Sevransky JE, Evans L, Landsittel D. Severe Acute Respiratory Infection-Preparedness: Protocol for a Multicenter Prospective Cohort Study of Viral Respiratory Infections. Crit Care Explor. 2022 Oct;4(10):e0773. PubMed PMID: 36284548
  • Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman J, Trooskin SB, Lo Re V 3rd. The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population. Open Forum Infect Dis. 2022 Sep;9(9):ofac445. PubMed PMID: 36092829
  • Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, Prendergast SJ, Gunter J, Rowan SE. A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probation. Health Justice. 2022 Aug 10;10(1):26. PubMed PMID: 35947313
  • Adje YH, Brooks KM, Castillo-Mancilla JR, Wyles DL, Anderson PL, Kiser JJ. The use of technology-based adherence monitoring in the treatment of hepatitis C virus. Ther Adv Infect Dis. 2022 Jan-Dec;9:20499361221095664. PubMed PMID: 35591885
  • Haukoos JS, Rowan SE, Galbraith JW, Rothman RE, Hsieh YH, Hopkins E, Houk RA, Toerper MF, Kamis KF, Morgan JR, Linas BP, Al-Tayyib AA, Gardner EM, Lyons MS, Sabel AL, White DAE, Wyles DL. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. Trials. 2022 Apr 25;23(1):354. PubMed PMID: 35468807
  • Brooks KM, Castillo-Mancilla JR, Morrow M, Mawhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah L, Tehrani A, Jimmerson LC, Roon L, Bushman LR, Anderson PL, Kiser JJ. Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use. J Antimicrob Chemother. 2022 Apr 27;77(5):1396-1403. PubMed PMID: 35194648
  • Auma AWN, Shive C, Damjanovska S, Kowal C, Cohen DE, Bhattacharya D, Alston-Smith B, Osborne M, Kalayjian R, Balagopal A, Sulkowski M, Wyles D, Anthony DD. T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. Open Forum Infect Dis. 2021 Apr;8(4):ofab079. PubMed PMID: 33880389
  • Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, Prendergast SJ, Rowan SE. Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City. Open Forum Infect Dis. 2022 Feb;9(2):ofab636. PubMed PMID: 35111867
  • Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317. PubMed PMID: 35026142
  • Aronsohn AI, Bhattacharya D, Morgan TR, Wyles DL, Chung RT, McQuillen DP. Reply. Hepatology. 2022 Apr;75(4):1055-1056. PubMed PMID: 34859470
  • Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis. 2021 Jan;8(1):ofaa564. PubMed PMID: 33447634
  • Sulkowski M, Wyles D. Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions. Clin Infect Dis. 2021 Nov 2;73(9):e3296-e3299. PubMed PMID: 32887999
  • Rowan SE, Wyles DL. Don't put off until tomorrow what you can do today: Hospital admissions as an opportunity to treat hepatitis C. Clin Infect Dis. 2023 Nov 22. [Epub ahead of print] PubMed PMID: 37991385
  • Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS). Open Forum Infect Dis. 2023 Mar;10(3):ofad115. PubMed PMID: 37008564
  • Anesi GL, Andrews A, Bai HJ, Bhatraju PK, Brett-Major DM, Broadhurst MJ, Campbell ES, Cobb JP, Gonzalez M, Homami S, Hypes CD, Irwin A, Kratochvil CJ, Krolikowski K, Kumar VK, Landsittel DP, Lee RA, Liebler JM, Lutrick K, Marts LT, Mosier JM, Mukherjee V, Postelnicu R, Rodina V, Segal LN, Sevransky JE, Spainhour C, Srivastava A, Uyeki TM, Wurfel MM, Wyles D, Evans L. Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic. Crit Care Med. 2023 Apr 1;51(4):445-459. PubMed PMID: 36790189
  • Rowan SE, Haukoos J, Kamis KF, Hopkins E, Gravitz S, Lyle C, Al-Tayyib AA, Gardner EM, Galbraith JW, Hsieh YH, Lyons MS, Rothman RE, White DAE, Morgan JR, Linas BP, Sabel AL, Wyles DL. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis C. Trials. 2023 Jan 27;24(1):63. PubMed PMID: 36707909
  • Bhatraju PK, Morrell ED, Stanaway IB, Sathe NA, Srivastava A, Postelnicu R, Green R, Andrews A, Gonzalez M, Kratochvil CJ, Kumar VK, Hsiang TY, Gale M Jr, Anesi GL, Wyles D, Broadhurst MJ, Brett-Major D, Mukherjee V, Sevransky JE, Landsittel D, Hung C, Altemeier WA, Gharib SA, Uyeki TM, Cobb JP, Liebler JM, Crosslin DR, Jarvik GP, Segal LN, Evans L, Mikacenic C, Wurfel MM. Angiopoietin-Like4 Is a Novel Marker of COVID-19 Severity. Crit Care Explor. 2023 Jan;5(1):e0827. PubMed PMID: 36600780

Practice Locations

Hospital Affiliation
  • Denver Health Medical Center

Specialty Information

Specialties
  • Infectious Disease, Board Certification (2003, 2023)

School of Medicine

CU Anschutz
Fitzsimons Building

13001 East 17th Place

Aurora, CO 80045

303.724.5375

School
General
Students